Neogenix Oncology, Inc. v. Gordon

133 F. Supp. 3d 539, 2015 WL 5774171, 2015 U.S. Dist. LEXIS 135663
CourtDistrict Court, E.D. New York
DecidedSeptember 30, 2015
DocketNo. 14-CV-4427 JFB AKT
StatusPublished
Cited by10 cases

This text of 133 F. Supp. 3d 539 (Neogenix Oncology, Inc. v. Gordon) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Neogenix Oncology, Inc. v. Gordon, 133 F. Supp. 3d 539, 2015 WL 5774171, 2015 U.S. Dist. LEXIS 135663 (E.D.N.Y. 2015).

Opinion

MEMORANDUM AND ORDER

JOSEPH F. BIANCO, District Judge:

This action arises from a company’s efforts to raise capital by offering financial incentives to intermediaries who attracted investors. Plaintiff Neogenix Oncology, Inc., (“Neogenix,” the “Company,” or “plaintiff’) brings this action' against its former attorneys and executives, alleging that they knowingly permitted the Company to raise money by paying finders’ fees to unlicensed brokers. According to Neo-genix, this illegal fundraising program, known as the “Finder Fee Program” (“FFP”), ultimately drove the company into bankruptcy, because potential investors were scared off once the company’s financial and legal exposure came to light.

Presently before the Court are separate motions to dismiss filed by defendants Peter Gordon; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. (“Mintz”); Nixon Peabody LLP (“Nixon”); Daniel J. Scher; Harry Gurwitch; and Maie Lewis, as representative of the estate of Brian Lewis (collectively, “defendants”). All defendants argue that plaintiffs claims are barred by the in pari delicto doctrine and the Wagoner rule because the conduct at issue is attributable to Neogenix and benefited the Company, and, therefore, plaintiff is precluded from bringing suit for harms caused by its own misdeeds. Defendants also argue that plaintiff has failed to adequately allege that their conduct caused' plaintiffs eventual bankruptcy, because Neogenix made statements during the course of its bankruptcy that suggest its financial condition was caused by other problems in the Company, and the claims for damages related to the bankruptcy must, therefore, be denied. Defendant Mintz separately argues that plaintiffs claims against it for breach of fiduciary duty and aiding and abetting a breach of fiduciary duty are barred on statute of limitations grounds and are duplicative of each other. Defendants Gurwitch and Lewis argue that plaintiffs claims against them for breach of fiduciary duty fail because plaintiff has not adequately pled that they owed a fiduciary duty to the Company, and that even if they did owe such a duty, their alleged conduct did not breach that duty or cause plaintiff damages. Defendant Scher, who became plaintiffs Chief Legal Officer (“CLO”) in 2010, argues that plaintiff has failed to allege that he engaged in any misconduct to substantiate a legal malpractice claim. Finally, defendant Gordon, plaintiffs Chief Financial Officer (“CFO”), argues that plaintiff has failed to allege that he engaged in any misconduct.

For the following reasons, the motions are denied. In short, defendants’ arguments all raise issues of fact that cannot be resolved in this particular case in the context of a motion to dismiss. For present purposes, it is sufficient that plaintiff has plausibly alleged that actions of Gordon in initiating and promoting the FFP were adverse to the Company’s interests, and thus plaintiffs claims are not barred by [544]*544any defense based upon a theory of attribution. The Court also concludes that plaintiff has plausibly alleged that defendants’ conduct contributing to the liabilities incurred by the FFP was a “but for” cause of the Company’s bankruptcy-related damages. The Court also concludes that plaintiff has plausibly alleged that Mintz, after initially advising Gordon of the FFP’s illegality, breached its fiduciary duty by intentionally failing to advise other Company officers or directors after Gordon moved forward with the FFP. Finally, the Court finds that plaintiff has plausibly alleged that the Company’s other legal advisers (Nixon and Scher) committed malpractice by failing to advise the Company of the FFP’s illegality, that Gurwitch and Lewis breached their fiduciary duties by failing to adequately advise the Company on the issues relating to the FFP due to their conflicts of interest, and that Gordon engaged in misconduct through his involvement in the FFP.

I. BACKGROUND

The following facts are taken from the amended complaint, and are not findings of fact by the Court. Instead, the Court will assume these facts to be true and, for purposes of the pending motion to dismiss, will construe them in a light most favorable to plaintiff, the non-moving party.

According to the amended complaint, “Neogenix was a biotechnology company that developed diagnostic and therapeutic products for the early detection and treatment of cancers.” (Am. Compl. ¶ 16.) Neogenix was incorporated in Maryland and headquartered in Great Neck, New York. (Id. ¶ 4.) In 2005, the Company embarked on a major initiative to raise capital, central to which was the FFP devised by Peter Gordon, the Company’s CFO. (Id. ¶ 25-28.) Under the program, Neogenix paid commissions to individuals who brokered sales of the company’s stock. (Id. ¶ 26.) Importantly, the FFP was not restricted to brokers who were licensed under state and federal laws; instead, the FFP enabled the Company to pay commissions to individuals regardless of their licensing status. (Id. ¶¶ 29-31.)

At the time Gordon initiated the FFP, Neogenix was represented by the law firm of Mintz, which served as outside general counsel to the Company. (Id. ¶ 35.) At the time of the FFP’s inception, a Mintz attorney advised Gordon that the proposed plan was unlawful, stating: ‘Your draft provides for the payment of commissions to officers and employees who sell units. You cannot pay compensation to non-licensed intermediaries.” (Id. ¶ 36.) Gordon did not convey this warning to other officers or directors of the Company, and the Company proceeded to raise significant funds through the FFP. (Id. ¶¶ 37-38). Specifically, Neogenix avers that “[b]y October 2011, Neogenix had compensated unlicensed finders millions of dollars in commissions for their securing tens of millions of dollars in investment capital.” (Id. ¶ 32.) During that time, Mintz attorneys who participated in Board meetings where the FFP was discussed never notified the Company that the program permitted unlawful activity. (Id. ¶¶ 39-51.) Although Neogenix was aware of the FFP, the Company was not aware that paying commissions to unregistered brokers was unlawful. (Id. ¶ 29.) Among these unlicensed intermediaries receiving commissions for referrals via the FFP were friends of Gordon — Gurwitch, Lewis, and Squire — all of whom also happened to be members of the Company’s Business Advisory Board, which was charged with advising the Company and its Board on business decisions and policies, including monitoring and oversight of the FFP.1 (Id. [545]*545¶¶ 94-98.) According to the amended complaint, Gordon also convinced Neoge-nix to hire Squire, Lewis, and Gurwitch and their respective companies (after they had been placed onto the Business Advisory Board) for various lucrative Company projects, including as financial advisors for fundraising and as investment banking service providers. (Id. ¶ 96.)

In 2008, the Mintz attorneys who handled Neogenix’s representation left that firm to join Nixon, where they continued to represent Neogenix. (Id. ¶ 61.) Neo-genix avers that “[a]s was the case with Mintz, Nixon was the Board’s sole source of legal advice until the company hired in-house counsel in early 2010.” (Id. ¶ 63.) Additionally, Neogenix asserts that

[l]ike Mintz, Nixon had many other opportunities to notify Neogenix of the impropriety associated with paying commissions to unlicensed finders and the risks that the Finder Fee Program created for Neogenix.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
133 F. Supp. 3d 539, 2015 WL 5774171, 2015 U.S. Dist. LEXIS 135663, Counsel Stack Legal Research, https://law.counselstack.com/opinion/neogenix-oncology-inc-v-gordon-nyed-2015.